BackgroundClinical manifestations of Parkinson’s disease (PD) after Corona Virus Disease 2019 (COVID-19) infection are poorly investigated.ObjectiveWe aimed to explore the clinical features and outcomes of hospitalized PD patients with COVID-19.MethodsA total of 48 PD patients and 96 age-and sex-matched non-PD patients were included. Demographics, clinical characteristics and outcomes were compared between two groups.ResultsPD patients with COVID-19 were elderly (76.69 ± 9.21 years) with advanced stage (H-Y stage 3–5 as 65.3%). They had less clinical symptoms (nasal obstruction, etc.), more proportions of severe/critical COVID-19 clinical classification (22.9 vs. 1.0%,p< 0.001), receiving oxygen (29.2 vs. 11.5%,p= 0.011), antibiotics (39.6 vs. 21.9%,p= 0.031) therapies, as well as longer hospitalization duration (11.39 vs. 8.32,p= 0.001) and higher mortality (8.3% vs. 1.0%,p= 0.001) relative to those without PD. Laboratory results showed that the PD group had higher white blood cell counts (6.29 vs. 5.16*109,p= 0.001), neutrophil-to-lymphocyte ratio (3.14 vs. 2.11,p< 0.001) and C-reactive protein level (12.34 vs. 3.19,p< 0.001).ConclusionPD patients with COVID-19 have insidious clinical manifestation, elevated proinflammatory markers and are prone to the development of severe/critical condition, contributing to a relatively poor prognosis. Early identification and active treatment of COVID-19 are pivotal to advanced PD patients during the pandemic.